News

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...
Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...
Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...
The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...
Hundreds of current and former workers at the Department of Health and Human Services (HHS) have penned a letter to Robert F Kennedy Jr, asking him to stop spreading misinformation that is inciting ...
A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.
Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...
Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...
According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...
And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to ...